Pyxis Oncology, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Pyxis Oncology, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $47.00K.
- Pyxis Oncology, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-12-31 was $3.00K.
- Pyxis Oncology, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $48.00K, a 1500.00% increase year-over-year.
- Pyxis Oncology, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $245.00K.
- Pyxis Oncology, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $632.00K, a 113.51% increase from fiscal 2024.
- Pyxis Oncology, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $296.00K, a 146.67% increase from fiscal 2023.
- Pyxis Oncology, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $120.00K, a 34.43% decline from fiscal 2022.
- Pyxis Oncology, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $183.00K, a 7.65% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $47.00K 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $632.00K 10-K · filed 2026-03-23 | |
| 2024-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $296.00K 10-K · filed 2026-03-23 |
| 2024-06-30 | $48.00K 10-Q · filed 2025-08-14 | $410.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $245.00K 10-Q · filed 2025-08-14 | $365.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $120.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | $117.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $3.00K 10-Q · filed 2024-08-14 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $183.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $6.00K 10-Q · filed 2023-11-07 | $339.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $1.00K 10-Q · filed 2023-08-11 | $336.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $176.00K 10-Q · filed 2023-08-11 | |
| 2021-12-31 | $156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $170.00K 10-K · filed 2023-03-22 |
| 2021-09-30 | $3.00K 10-Q · filed 2022-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |